Dry powder inhalers for optimal drug delivery

Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30 years. In the last decade there has been a big increase in DPI development, resulting partly from recognised limitations in other types of inhaler device. Many companies are developing DPIs for asthma and chronic obstructive pulmonary disease (COPD) therapy, and there is increasing recognition of the potential role of DPI systems for other therapies, such as inhaled antibiotics and peptides/proteins. Optimised drug delivery may be achieved not only by improvements to devices, but also via more sophisticated formulations that disperse easily in the inhaled air-stream and which may often be delivered by relatively simple inhaler devices. DPIs could become the device category of choice for a wide range of inhaled therapies, involving both local and systemic drug delivery.

[1]  Jim Wright,et al.  Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[2]  L. Borgström,et al.  On the use of dry powder inhalers in situations perceived as constrained. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[3]  M. Newhouse,et al.  Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. , 2003, Chest.

[4]  W. Busse,et al.  Evolution of dry powder inhaler design, formulation, and performance. , 2002, Respiratory medicine.

[5]  S. Newman,et al.  Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers , 1999, Clinical pharmacokinetics.

[6]  Kjell Wetterlin,et al.  Turbuhaler: A New Powder Inhaler for Administration of Drugs to the Airways , 1988, Pharmaceutical Research.

[7]  Hans Bisgaard.  Automatic actuation of a dry powder inhaler into a nonelectrostatic spacer. , 1998, American journal of respiratory and critical care medicine.

[8]  A. Woodcock,et al.  Chlorofluorocarbon-free inhalers: are we ready for the change? , 1998, The European respiratory journal.

[9]  E. Barrett,et al.  Inhaled insulin , 2006, BMJ : British Medical Journal.

[10]  J. Patton.  Deep-lung delivery of therapeutic proteins , 1997 .

[11]  M. Hertog,et al.  Lung deposition of budesonide from the novel dry powder inhaler Airmax. , 2002, Respiratory medicine.

[12]  L. Borgström,et al.  Lung deposition of budesonide in asthmatics: a comparison of different formulations , 1998 .

[13]  G. P. Martin,et al.  Transition to CFC-free metered dose inhalers--into the new millennium. , 2000, International journal of pharmaceutics.

[14]  L. Borgström,et al.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. , 1994, The European respiratory journal.

[15]  G. Scheuch,et al.  In vitro and in vivo dose delivery characteristics of large porous particles for inhalation. , 2002, International journal of pharmaceutics.

[16]  R. Sharma,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler (P-MDI) , 1995, The European respiratory journal.

[17]  Sumby,et al.  Latest advances in the development of dry powder inhalers. , 2000, Pharmaceutical science & technology today.

[18]  A. R. Clark,et al.  Medical Aerosol Inhalers: Past, Present, and Future , 1995 .

[19]  S. Newman,et al.  Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler. , 2002, Respiratory medicine.

[20]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[21]  G K Crompton,et al.  Problems patients have using pressurized aerosol inhalers. , 1982, European journal of respiratory diseases. Supplement.

[22]  C. Leach,et al.  Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. , 1998, The European respiratory journal.

[23]  T Lankinen,et al.  Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. , 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[24]  R. Hermann,et al.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.

[25]  A. Hollingworth,et al.  The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing. , 1993, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[26]  Stephen P. Newman,et al.  Improved Lung Delivery from a Passive Dry Powder Inhaler Using an Engineered PulmoSphere® Powder , 2002, Pharmaceutical Research.

[27]  S. Li,et al.  Drug delivery performance of the mometasone furoate dry powder inhaler. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[28]  S. Newman,et al.  Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. , 1997, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[29]  Lars Borgström,et al.  Dry-Powder Inhalers , 2001 .

[30]  G. Keating,et al.  Airmax: a multi-dose dry powder inhaler. , 2002, Drugs.

[31]  G P Martin,et al.  The influence of carrier morphology on drug delivery by dry powder inhalers. , 2000, International journal of pharmaceutics.

[32]  王姮,et al.  Inhaled insulin , 2005 .

[33]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[34]  U. Lalloo.  Symbicort: controlling asthma in adults. , 2002, Respiratory medicine.

[35]  M. Parry-Billings,et al.  The inhalers of the future? A review of dry powder devices on the market today. , 2003, Pulmonary pharmacology & therapeutics.

[36]  York,et al.  Strategies for particle design using supercritical fluid technologies. , 1999, Pharmaceutical science & technology today.

[37]  G. Taplin,et al.  Prevention of postoperative pulmonary infections; inhalation of micropowdered penicillin and streptomycin. , 1948, Journal of the American Medical Association.

[38]  F. Morén,et al.  Aerosols in Medicine: Principles, Diagnosis and Therapy , 1993 .